What Global Stem cell Technology does

Global Stem cell Technology (GST) is a privately held veterinary biotechnology company headquartered in Evergem, Belgium, founded in 2012. According to its firmographic profile, the company develops and produces stem cell products intended for veterinary applications, positioning it within the animal health cell-therapy niche rather than human regenerative medicine. Its website (gst.be) and Belgian operating base suggest a European focus, though the "Global" in its name implies ambition for international distribution of its veterinary stem cell offerings.

The company is structured as a for-profit private entity, and operates in a specialized segment — manufacturing biological products derived from stem cells for use in animal patients. Veterinary stem cell therapy is a regulated product category that typically requires biologic-equivalent approvals, cold-chain logistics, and clinical validation, all of which shape GST's likely operating model around batch manufacturing, quality-controlled release, and distribution through veterinary clinics or specialty animal hospitals.

The available input data is materially thin: the only retrieved web source was a SiteManager Dashboard login page that contained no company-specific information. Consequently, no confirmed product SKUs, named customers, pricing model, headcount, funding history, partnership roster, regulatory certifications, or revenue figures are available to substantiate further description. Any diligence effort should treat the above as preliminary framing and prioritize primary-source collection (management interviews, regulatory filings, customer references) before drawing material investment conclusions.

Name

Global Stem cell Technology

Website

https://gst.be

Company type

Private

Founded year

2012

Short description

Global Stem cell Technology is a Belgian veterinary biotech founded in 2012 that develops and produces stem cell products for animal health applications, operating from Evergem, Belgium as a privately held for-profit company.

Ownership category

akta.pro rank

Product category

Veterinary Biotechnology

NAICS

Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Stem Cell Therapies (Autologous & Allogeneic) (HLAMANAA)

akta.pro secondary industries

Cell & Gene Therapy for Veterinary Regeneration (HLAMANAD), Veterinary Regenerative Medicine Manufacturing (GMP/CDMO, Cell Processing) (HLAMANAI)

Keywords

• Veterinary biotechnology
• Stem cell therapy
• Animal regenerative medicine
• Veterinary medicine
• Biological products

Headquarters

HQ city

Evergem

HQ country

Belgium

HQ region

Europe

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Supply Chain

Core offering

Global Stem cell Technology is a veterinary biotechnology company that develops and produces state-of-the-art stem cell products. The company's offerings focus on regenerative medicine applications for animal health, supplying biological stem cell preparations to veterinary practitioners.

Differentiator

Problem solved

Functional benefit

Products and services

• Stem cell products (veterinary) State-of-the-art stem cell products developed and produced by Global Stem cell Technology for use in veterinary regenerative medicine and animal health treatments.

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Broad incumbents

• Dechra Pharmaceuticals: Specialty veterinary pharmaceuticals company with strong European footprint. Comparable European-based animal health manufacturer relevant to Global Stem cell Technology's geography and category.
• Elanco Animal Health: Major global animal health company with a diverse portfolio of veterinary therapeutics. Comparable as a scaled veterinary medicines manufacturer, though broader in scope than stem cell specialization.
• Zoetis: World's largest pure-play animal health company offering a wide range of veterinary pharmaceuticals and biologics. Broadly comparable industry positioning with adjacent biologics capabilities.
• Boehringer Ingelheim Animal Health: Global animal health pharmaceutical leader with a broad veterinary biologics portfolio. Comparable as a large-scale developer and manufacturer of veterinary therapeutics, though not specialized in stem cells.

Direct peers

• MediVet Biologics: Animal health company focused on regenerative veterinary therapies including stem cell and biologic treatments. Comparable as a developer and distributor of veterinary stem cell products.
• VetStem Biopharma: US-based veterinary regenerative medicine company specializing in autologous stem cell therapies for horses, dogs, and cats. Most direct comparable peer to Global Stem cell Technology's stated product mandate.
• Ardent Animal Health: Veterinary regenerative medicine provider offering stem cell and platelet-rich plasma therapies across companion animal and equine markets. Operates in the same veterinary stem cell product category.
• Animal Cell Therapies: Veterinary regenerative medicine company offering stem cell therapy services and products for companion animals. Directly comparable in product type and end customer base.
• EquiCell: Veterinary stem cell therapy provider focused on equine applications. Comparable niche specialization within veterinary regenerative medicine.

Emerging players

• Kindred Biosciences: Biopharmaceutical company developing novel therapies for companion animals, with biologics capabilities. Comparable as a smaller, focused veterinary biologics developer.

Market position

Strengths3 records

Weaknesses3 records

Competitive moat3 records

Key risks4 records

Key highlights3 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Global Stem cell Technology